Literature DB >> 26920453

The pregnane X receptor down-regulates organic cation transporter 1 (SLC22A1) in human hepatocytes by competing for ("squelching") SRC-1 coactivator.

Lucie Hyrsova1, Tomas Smutny1, Alejandro Carazo1, Stefan Moravcik1, Jana Mandikova1, Frantisek Trejtnar1, Sabine Gerbal-Chaloin2,3, Petr Pavek1.   

Abstract

BACKGROUND AND
PURPOSE: The organic cation transporter 1 (OCT1) transports cationic drugs into hepatocytes. The high hepatic expression of OCT1 is controlled by the HNF4α and USF transcription factors. Pregnane X receptor (PXR) mediates induction of the principal xenobiotic metabolizing enzymes and transporters in the liver. Here, we have assessed the down-regulation of OCT1 expression by PXR activation. EXPERIMENTAL APPROACH: We used primary human hepatocytes and related cell lines to measure OCT1 expression and activity, by assaying MPP(+) accumulation. Western blotting, qRT-PCR, the OCT1 promoter gene reporter constructs and chromatin immunoprecipitation assays were also used. KEY
RESULTS: OCT1 mRNA in human hepatocytes was down-regulated along with reduced [(3) H]MPP(+) accumulation in differentiated HepaRG cells after treatment with rifampicin. Rifampicin and hyperforin as well as the constitutively active PXR mutant T248D suppressed activity of the 1.8 kb OCT1 promoter construct in gene reporter assays. Silencing of both PXR and HNF4α in HepaRG cells blocked the PXR ligand-mediated down-regulation of OCT1 expression. The mutation of HNF4α and USF1 (E-box) responsive elements reversed the PXR-mediated inhibition in gene reporter assays. Chromatin immunoprecipitation assays indicated that PXR activation sequestrates the SRC-1 coactivator from the HNF4α response element and E-box of the OCT1 promoter. Consistent with these findings, exogenous overexpression of the SRC-1, but not the PGC1α coactivator, relieved the PXR-mediated repression of OCT1 transactivation. CONCLUSIONS AND IMPLICATIONS: PXR ligands reduced the HNF4α-mediated and USF-mediated transactivation of OCT1 gene expression by competing for SRC-1 and decreased delivery of a model OCT1 substrate into hepatocytes.
© 2016 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26920453      PMCID: PMC4842917          DOI: 10.1111/bph.13472

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  38 in total

1.  Rifampin enhances the glucose-lowering effect of metformin and increases OCT1 mRNA levels in healthy participants.

Authors:  S K Cho; J S Yoon; M G Lee; D H Lee; L A Lim; K Park; M S Park; J-Y Chung
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875

Review 2.  HNF4: a central regulator of hepatocyte differentiation and function.

Authors:  Alistair J Watt; Wendy D Garrison; Stephen A Duncan
Journal:  Hepatology       Date:  2003-06       Impact factor: 17.425

3.  Experimental design and analysis and their reporting: new guidance for publication in BJP.

Authors:  Michael J Curtis; Richard A Bond; Domenico Spina; Amrita Ahluwalia; Stephen P A Alexander; Mark A Giembycz; Annette Gilchrist; Daniel Hoyer; Paul A Insel; Angelo A Izzo; Andrew J Lawrence; David J MacEwan; Lawrence D F Moon; Sue Wonnacott; Arthur H Weston; John C McGrath
Journal:  Br J Pharmacol       Date:  2015-07       Impact factor: 8.739

4.  Infection of a human hepatoma cell line by hepatitis B virus.

Authors:  Philippe Gripon; Sylvie Rumin; Stephan Urban; Jacques Le Seyec; Denise Glaise; Isabelle Cannie; Claire Guyomard; Josette Lucas; Christian Trepo; Christiane Guguen-Guillouzo
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-13       Impact factor: 11.205

5.  Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin.

Authors:  De-Sheng Wang; Johan W Jonker; Yukio Kato; Hiroyuki Kusuhara; Alfred H Schinkel; Yuichi Sugiyama
Journal:  J Pharmacol Exp Ther       Date:  2002-08       Impact factor: 4.030

Review 6.  Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3).

Authors:  Johan W Jonker; Alfred H Schinkel
Journal:  J Pharmacol Exp Ther       Date:  2003-10-23       Impact factor: 4.030

7.  Evidence that the pregnane X and retinoid receptors PXR, RAR and RXR may regulate transcription of the transporter hOCT1 in chronic myeloid leukaemia cells.

Authors:  Gemma Austin; Alison Holcroft; Natasha Rinne; Lihui Wang; Richard E Clark
Journal:  Eur J Haematol       Date:  2014-07-31       Impact factor: 2.997

8.  Functional inhibitory cross-talk between constitutive androstane receptor and hepatic nuclear factor-4 in hepatic lipid/glucose metabolism is mediated by competition for binding to the DR1 motif and to the common coactivators, GRIP-1 and PGC-1alpha.

Authors:  Ji Miao; Sungsoon Fang; Yangjin Bae; Jongsook Kim Kemper
Journal:  J Biol Chem       Date:  2006-02-21       Impact factor: 5.157

9.  SRC-1 and GRIP1 coactivate transcription with hepatocyte nuclear factor 4.

Authors:  Jen-Chywan Wang; John M Stafford; Daryl K Granner
Journal:  J Biol Chem       Date:  1998-11-20       Impact factor: 5.157

10.  The role of hepatic transport and metabolism in the interactions between pravastatin or repaglinide and two rOatp inhibitors in rats.

Authors:  Lassina Badolo; Christoffer Bundgaard; Mats Garmer; Bente Jensen
Journal:  Eur J Pharm Sci       Date:  2013-05-03       Impact factor: 4.384

View more
  9 in total

1.  Transcriptional Regulation of Solute Carrier (SLC) Drug Transporters.

Authors:  Shiwei Zhou; Yan Shu
Journal:  Drug Metab Dispos       Date:  2022-05-29       Impact factor: 3.579

Review 2.  Pregnane X Receptor (PXR)-Mediated Gene Repression and Cross-Talk of PXR with Other Nuclear Receptors via Coactivator Interactions.

Authors:  Petr Pavek
Journal:  Front Pharmacol       Date:  2016-11-25       Impact factor: 5.810

3.  Role of OCT1 in hepatocellular carcinoma.

Authors:  Jingguo Li; Zhengyi Yang; Biguang Tuo
Journal:  Onco Targets Ther       Date:  2019-07-25       Impact factor: 4.147

Review 4.  Regulation of PXR Function by Coactivator and Corepressor Proteins: Ligand Binding Is Just the Beginning.

Authors:  Juan Pablo Rigalli; Dirk Theile; Julie Nilles; Johanna Weiss
Journal:  Cells       Date:  2021-11-12       Impact factor: 6.600

5.  Hepatic Transporter Alterations by Nuclear Receptor Agonist T0901317 in Sandwich-Cultured Human Hepatocytes: Proteomic Analysis and PBPK Modeling to Evaluate Drug-Drug Interaction Risk.

Authors:  Katsuaki Ito; Noora Sjöstedt; Melina M Malinen; Cen Guo; Kim L R Brouwer
Journal:  J Pharmacol Exp Ther       Date:  2020-03-03       Impact factor: 4.030

6.  Rifampicin Induces Gene, Protein, and Activity of P-Glycoprotein (ABCB1) in Human Precision-Cut Intestinal Slices.

Authors:  Ondrej Martinec; Carin Biel; Inge A M de Graaf; Martin Huliciak; Koert P de Jong; Frantisek Staud; Filip Cecka; Peter Olinga; Ivan Vokral; Lukas Cerveny
Journal:  Front Pharmacol       Date:  2021-06-09       Impact factor: 5.810

7.  Teriflunomide Is an Indirect Human Constitutive Androstane Receptor (CAR) Activator Interacting With Epidermal Growth Factor (EGF) Signaling.

Authors:  Alejandro Carazo; Jan Dusek; Ondrej Holas; Josef Skoda; Lucie Hyrsova; Tomas Smutny; Tomas Soukup; Martin Dosedel; Petr Pávek
Journal:  Front Pharmacol       Date:  2018-10-11       Impact factor: 5.810

8.  PLGA Based Nanospheres as a Potent Macrophage-Specific Drug Delivery System.

Authors:  Barbora Boltnarova; Jana Kubackova; Josef Skoda; Alzbeta Stefela; Monika Smekalova; Petra Svacinova; Ivona Pavkova; Milan Dittrich; Daniel Scherman; Jarmila Zbytovska; Petr Pavek; Ondrej Holas
Journal:  Nanomaterials (Basel)       Date:  2021-03-16       Impact factor: 5.076

9.  PXR Suppresses PPARα-Dependent HMGCS2 Gene Transcription by Inhibiting the Interaction between PPARα and PGC1α.

Authors:  Ryota Shizu; Kanako Ezaki; Takumi Sato; Ayaka Sugawara; Takuomi Hosaka; Takamitsu Sasaki; Kouichi Yoshinari
Journal:  Cells       Date:  2021-12-16       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.